Signum Surgical: Dr Bernard Collins

Signum Surgical, a Galway-based medical technology company developing solutions to treat colorectal diseases, has appointed Dr Bernard Collins as a non-executive director.

Collins is on the board of several US and Irish life-science companies including, CroíValve, Aerogen, Atlantic Therapeutics and Vivasure Medical. He was formerly vice-president of international operations for Boston Scientific for 10 years and has held a number of senior executive positions in international life-science companies, including at Baxter Healthcare.

Jeff Grainger, chairman of Signum Surgical, said: “As we continue to progress our regulatory and clinical programmes, Bernard brings a wealth of commercial experience and technical expertise at an important time for the company. We look forward to his contribution.”

Signum Surgical is focused on developing minimally invasive technologies to treat colorectal diseases, principally the condition known as anal fistula. This painful, and often recurring colorectal condition, which severely affects patients’ quality of life, involves the infection of an internal gland. Affecting one in 5,000 people worldwide, patients and their physicians are dissatisfied with current treatment options, which are rarely successful, and can leave patients suffering with ongoing infections which require repeat procedures.

Developed in collaboration with expert colorectal surgeons, Signum Surgical’s BioHealx technology, which enables surgeons to treat anal fistula with a minimally invasive outpatient procedure, features a single use, bioabsorbable, implant that is designed to help seal the fistula tract and dissolve in the body after treatment. The single-operation approach is designed to promote healing, prevent reinfection, and protect patient continence.

Collins said: “I look forward to helping the team accelerate its regulatory and commercial objectives. I believe in Signum Surgical’s innovative BioHealx technology as an effective and viable treatment option for physicians, which has the potential to transform the lives of patients suffering from an anal fistula.”

Join our mailing list

Stay up to date with all our events, awards and publications.

Information you provide us with will be kept private at all times, and will be used for communication and research purpose only.